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Abstract
With the introduction of direct-acting antiviral agents 
(DAA), the rate of sustained virological response (SVR) 
in the treatment of hepatitis C virus (HCV) has radically 
improved to over 95%. Robust scientific evidence sup-
ports a beneficial role of SVR after interferon therapy 
in the progression of cirrhosis, resulting in a decreased 
incidence of hepatocellular carcinoma (HCC). However, 
a debate on the impact of DAAs on the development 
of HCC is ongoing. This review aimed to analyse the 
scientific literature regarding the risk of HCC in terms of 
its recurrence and occurrence after the use of DAAs to 
eradicate HCV infection. Among 11 studies examining 
HCC occurrence, the de novo incidence rate ranged 
from 0 to 7.4% (maximum follow-up: 18 mo). Among 
18 studies regarding HCC recurrence, the rate ranged 
from 0 to 54.4% (maximum “not well-defined” follow-
up: 32 mo). This review highlights the major difficulties 
in interpreting data and reconciling the results of the 
included studies. These difficulties include heterogeneous 
cohorts, potential misclassifications of HCC prior to DAA 
therapy, the absence of an adequate control group, short 
follow-up times and different kinds of follow-up. Moreover, 
no clinical feature-based scoring system accounts for the 
molecular characteristics and pathobiology of the tumours. 
Nonetheless, this review does not suggest that there is a 
higher rate of de novo HCC occurrence or recurrence after 
DAA therapy in patients with previous HCV infection.
Key words: Hepatocellular carcinoma; Hepatitis C virus; 
Direct-acting antiviral agents; Occurrence; Recurrence
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Core tip: A significant debate about the impact of direct-
acting antiviral agents (DAAs) on the development of 
hepatocellular carcinoma (HCC) is currently ongoing. 
After a full review of the published literature, the evi-
dence does not suggest that there is a higher rate of de 
novo HCC occurrence or recurrence after DAA therapy in 
patients with previous hepatitis C virus infection.
Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco 
F; on behalf of the Special Interest Group on “Hepatocellular 
carcinoma and new anti-HCV therapies” of the Italian 
Association for the Study of the Liver. Direct-acting antivirals and 
hepatocellular carcinoma in chronic hepatitis C: A few lights and 
many shadows. World J Gastroenterol 2018; 24(24): 2582-2595 
Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/
i24/2582.htm  DOI: http://dx.doi.org/10.3748/wjg.v24.i24.2582
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading 
cause of cancer-related death worldwide. Cirrhosis is 
the strongest risk factor for HCC, and chronic hepatitis C 
(HCV) is the most common underlying aetiology in both 
the United States and Europe[1].
The annual risk of developing HCC in HCV-related cir-
rhotic patients is approximately 2%-8%[2].
Though curative treatments, such as liver resection 
(LR) and radiofrequency ablation (RFA), exist, once HCC 
develops, the rate of cumulative recurrence is known to 
be approximately 70% over 5 years[3].
Since 2013, the treatment of hepatitis C has dra-
matically changed. The generation of new direct-
acting antiviral agents (DAAs) has been extraordinarily 
effective, safe and well-tolerated. These DAAs have 
spurred a revolution in the treatment of HCV patients, 
showing sustained virological response (SVR) rates 
exceeding 95% in real-life settings[4]. This tremendous 
advancement has provided therapeutic options for a 
larger number of patients, many of which have advanced 
liver disease and a higher risk of liver decompensation 
and HCC.
Over the past two decades, several meta-analyses 
have evaluated the role of SVR in preventing hepatic 
decompensation, reducing the necessity for liver trans-
plantation, increasing both liver-related and overall 
survival, and reducing the risk of occurrence and recur-
rence of HCC in HCV cirrhotic patients. Studies from 
the interferon (IFN)-era taught us that HCV eradication 
reduces but does not eliminate the risk of HCC once 
cirrhosis has been established[5]. Accordingly, Nishiguchi 
et al[6] demonstrated that IFN reduced the incidence of 
HCC in patients with HCV infection and cirrhosis and 
showed that IFN might improve the prognosis of cirrhotic 
patients by improving liver function and by delaying the 
development or growth of hepatocellular carcinoma.
However, the impact that an SVR from a DAA regi-
men has on liver cancer occurrence and recurrence 
seems to be controversial. Due to the possibility of 
treating patients with more advanced liver disease, it is 
not surprising to observe the development of HCC after 
providing HCV therapy. In the spring of 2016, this topic 
became of particular interest because of the publication 
of two papers from Spain[7] and Italy[8] that suggested a 
potential increase in the occurrence and recurrence rates 
of HCC in patients who were treated with DAAs. Since 
these two original publications, more than 100 papers, 
letters and communications have also been published 
on this topic. Most of the controversies arise from the 
heterogeneity of populations, variations in the inclusion 
and exclusion criteria for each study, the follow-up time, 
the time points used to analyse the occurrence and 
recurrence rates, and so on. 
The debate in the scientific community is still ongoing. 
Thus, the aim of this review was to analyse the published 
data concerning the occurrence and recurrence of HCC 
after DAA treatment to reconcile the conflicting results 
between studies.
LITERATURE SEARCH
Original published studies were identified by searching 
PubMed, Embase, and the Cochrane Library database 
(through April 2018). English language articles were 
selected using the following keywords: ‘hepatocellular 
carcinoma’, ‘HCC’, ‘chronic hepatitis C’, ‘HCV’, ‘DAA’, 
‘direct-acting antivirals’, ‘occurrence’ and ‘recurrence.’ 
Two independent evaluators (MG and AS) identified all 
reports that may have pertained to the review issue. 
Case reports were excluded. A full-text evaluation was 
performed, and the references from relevant articles 
were reviewed to identify additional studies. Manual 
cross-referencing was performed, and relevant abstracts 
from the 2017 International Congress abstract books 
(AASLD and EASL) were included.
HCV-DAA AND HCC OCCURRENCE
Definition of HCC occurrence
HCC occurrence was defined as the de novo appearance 
of HCC in a subject (with or without an underlying liver 
disease) with no history or previous evidence or suspicion 
of a liver tumour.
The risk of HCC occurrence after DAA treatment
Recent studies have suggested that DAA may accelerate 
the occurrence of HCC in patients with liver cirrhosis. 
However, the annual risk of HCC in HCV-related cirrhotic 
patients is approximately 2%-8%[2]. Ultimately, the 
results of these studies did not show an increased risk 
of HCC in comparison to the expected annual risk for 
patients treated with DAAs. Table 1 summarises the 
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results of the principal studies addressing de novo HCC 
occurrence after DAA treatment. Figure 1 shows the de 
novo HCC cumulative incidence rates reported by 11 
studies.
The first paper published was by Conti et al[8]. The 
authors reported an HCC occurrence rate of 3.2% 
at 6 mo of follow-up after beginning DAA therapy. 
Similarly, Nakao et al[9] observed cumulative HCC 
incidences after 1 year and 2 years of DAA therapy of 
1.7% and 7%, respectively. Additionally, Cardoso et 
al[10] reported an HCC incidence of 7.4% in the first 
year after SVR from DAA treatment. This rate was 
higher than the previously reported incidence rate for 
IFN regimens (1.2%-1.4%)[10,11]. Median time for HCC 
development was 7.6 mo after HCV-RNA became non-
detectable[10]. Accordingly, Kozbial et al[12] reported an 
overall cumulative incidence of de novo HCC after DAA 
treatment of 6.6%, while this rate was 5.2% in patients 
achieving SVR, with a follow-up time of 48 wk.
In contrast to these initial observations, several lar-
ger studies found different results (Table 1). Kanwal 
et al[13] reported that cirrhotic patients with SVR had a 
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Ref. Journal, year Country Study design Sample 
size
Median follow-
up (mo)
HCC cumulative 
incidence (%)
Risk factors Notes
Conti et al[8] J Hepatol, 2016 Italy Retrospective 207 6 3.1 cirrhosis, child class 
B, low platelet count
No control group
Cheung et al[15] J Hepatol, 2016 United
Kindom
Prospective 406 18 5.4 in SVR group NA Control groups: 
Non-SVR with HCC 
incidence of 11.3%
Kozbial et al[12] J Hepatol, 2016 Austria Retrospective 16 NA 6.6 NA Letter to editor
Cardoso et al[10] J Hepatol, 2016 Portugal Retrospective 54 12 7.4 NA Letter to editor
Kanwal et al[13] Gastroenterology, 
2017
United
States
Retrospective 22500 NA 1.2 cirrhosis, alcohol use HCC incidence: 0.9% 
in SVR, 2.9% in non-
SVR
Zeng et al[18] J Hepatol, 2016 China Retrospective 21 15 0 NA Letter to editor
Calleja et al[14] J Hepatol, 2017 Spain Retrospective 3325 18   0.93 NA  - 
Ioannou et al[31] J Hepatol, 2017 United
States
Retrospective 21948 18 2 NA HCC incidence: 1.4% 
in SVR, 8.1% in non-
SVR
Mettke et al[17] Aliment Pharmacol 
Ther, 2017
Germany Prospective 158 15 3.7 MELD score, AFP 
level
HCC incidence in 
untreated: 7.6%
Nakao et al[9] J Hepatol, 2017 Japan Retrospective 242 15 2.8 NA Letter to editor
Calvaruso et al[19] Gastroenterology, 
2018
Italy PWrospective 2249 14 3.5 low albumin level, 
absence of SVR, low 
platelet count
The  rate of HCC at 1 
yr was 2.9%.
Table 1  Main characteristics of the studies on hepatocellular carcinoma occurrence
AFP: Alpha-fetoprotein; DAAs: Direct-acting antiviral agents; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; LR: Liver resection; LRT: 
Local-regional therapy; LT: Liver transplantation; SVR: Sustained virological response; RFA: Radiofrequency ablation; TACE: Trans-catheter arterial 
chemoembolization; NA: Not available.
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Figure 1  Hepatocellular carcinoma cumulative occurrence rates reported by 11 studies considered in the present review. HCC: Hepatocellular carcinoma; f.u.: 
Follow up; NA: Not available.
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90.5% Child-Pugh class A, 9.5% Child-Pugh class B) 
treated with DAA from March 2015 until July 2016 
in 22 academic and community liver centres in Sicily 
Region, Italy. Only 78 patients (3.4%) developed HCC 
during a mean observation of 14 mo from the start of 
DAA treatment; the overall cumulative rate of HCC at 
1 year was 2.9%. Of interest, the occurrence of HCC 
is significantly reduced in patients with compensated 
cirrhosis without signs of portal hypertension and normal 
liver function. Moreover, the authors did not support the 
hypothesis that HCC that develops during DAA or after 
early follow-up is more aggressive and more difficult to 
treat with available therapies. In fact, none of the 78 
patients had a multinodular or aggressive HCC pattern[19].
Several risk factors have been identified for HCC 
occurrence after DAA treatment (Table 1), such as 
HCV treatment failure, alcohol use, aged older than 65 
years, male gender, presence of cirrhosis, HCV genotype 
3 infection, diabetes, metabolic syndrome, HIV co-
infection, higher MELD scores, lower albumin level, lower 
platelet count,  and higher AFP levels[13,16,17,19,20].
In trying to summarize these data, we can conclude 
that de novo HCC occurrence risk does not appear to be 
reduced in the time immediately following DAA treatment 
compared to untreated patients. On the other hand, we 
do not have evidence to suggest that the occurrence rate 
increases either, as there was an absence of an adequate 
control group in most studies. Unfortunately, the risk of 
HCC does not vanish rapidly, and a longer observation 
period is probably necessary to observe any beneficial 
effects.
Comparing the risk of HCC occurrence after DAAs vs 
after IFN-based treatments
IFN-based regimens were approved for treating chronic 
hepatitis C more than 20 years ago. Many studies have 
demonstrated the long-term effects of this therapy in 
obtaining an SVR, which is considered a milestone in 
reducing the risk of liver-related complications, such as 
HCC[5,21-25].
However, though the benefits of this treatment in 
reducing HCC incidence are well documented, the risk is 
not completely removed in patients with severe fibrosis or 
cirrhosis. Such conditions occur with an annual incidence 
of 0.3%-1%[1]. These data were recently confirmed in an 
elegant study by D’Ambrosio et al[26], who investigated 
a cohort of 38 histological cirrhotic patients who had 
been prospectively followed for 10 years after achieving 
a SVR with IFN treatment. During a median follow-up of 
86 mo after a liver biopsy, no patients developed clinical 
decompensation, while 5 patients (13%) developed HCC. 
The 8-year cumulative probability of HCC was thus 17% 
regardless of the cirrhosis regression, while the 8-year 
cumulative survival probability was 97% regardless of 
the cirrhosis regression (96% vs 100%, p = 1.0) or HCC 
development (100% vs 97%, p = 1.0)[26].
Compared to IFN regimens, less consistent data are 
available concerning the impact of DAA therapy on HCC 
significantly reduced risk of HCC compared to patients 
without SVR (76% risk reduction). Moreover, they 
highlighted that the HCV-treated population has changed 
significantly in the DAA era and now includes many 
patients with other HCC risk factors (alcohol abuse, 
age older than 65 years and patients with advanced 
cirrhosis), which were previously criteria for exclusion 
from IFN therapy[13]. Because the risk of HCC in patients 
with HCV cirrhosis is 2%-8% per year[2] a 76% reduction 
represents a significant clinical advantage. In the largest 
real-world study, Calleja et al[14] enrolled almost 4000 
patients who were treated with DAAs. The study reported 
an HCC incidence rate of 0.93% within 18 mo of starting 
DAA treatment, though measuring the incidence of HCC 
was not an objective of this study. They also observed 
that HCC was more common in patients with cirrhosis, 
but this was not related to the achievement of a SVR[14]. 
Similarly, a prospective study by Cheung et al[15] exa-
mined 406 patients with decompensated cirrhosis 
through the English Expanded Access Programme. The 
study found no evidence of an increased risk for liver 
cancer during DAA therapy or over the following 12 mo. 
Moreover, for HCC developing within 3 mo of starting 
DAA treatment, the authors suggested that there was a 
possibility that the patients already had an undiagnosed 
cancer before starting the treatment[15]. Additionally, 
Hasson et al[16] reported similar results showing that 
DAA-based therapy in HIV/HCV co-infected patients did 
not show an increasing cancer trend during 24 wk of 
follow-up, though, as expected, a high rate of SVR was 
confirmed (97%). During standard surveillance (liver 
ultrasound and AFP every six months) for a median 
follow-up of 87 wk after beginning DAA treatment, de 
novo HCC was diagnosed in 3/118 (2.5%) patients with 
advanced liver disease. The authors concluded that strict 
surveillance is mandatory, especially in patients with 
additional known risk factors for HCC (e.g., advanced 
cirrhosis, genotype 3, diabetes, metabolic syndrome, 
HIV co-infection)[16]. Finally, in a large prospective study, 
Mettke et al[17] showed that patients with liver cirrhosis 
who received DAA therapy had a similar HCC incidence 
over a short time compared to an untreated historical 
control cohort that was recruited from the same centre 
(158 DAA-treated and 184 control patients with HCV 
liver cirrhosis). HCC developed in 6 DAA patients and 14 
untreated patients, yielding HCC incidence rates of 2.90 
and 4.48 per 100 person-years, respectively. Moreover, 
they identified that higher MELD scores and AFP levels 
are independent HCC risk factors[17]. Similarly, Zeng et 
al[18] reported no cases of HCC occurrence in their 21 
cirrhotic patients treated with 12 weeks of DAAs after a 
median follow-up time of 15 mo.
In the recent prospective observational study based 
on RESIST-HCV (Rete Sicilia Selezione Terapia - HCV), 
a web-based regional database, Calvaruso et al[19] 
confirmed the early benefit of viral eradication in HCV 
cirrhosis throughout all stages of cirrhosis. The authors 
analysed only patients with cirrhosis (2249 patients: 
Guarino M et al . DAA and HCC in HCV patients
2586 June 28, 2018|Volume 24|Issue 24|WJG|www.wjgnet.com
occurrence. Moreover, the HCC risk after DAA treatment 
compared to IFN treatment faces recruitment bias since 
two different types of patients are involved in these 
treatments. 
An interesting manuscript by Lu et al[27] showed 
data from a long-term follow-up for HCC detection in 
numerous HCV cohorts, including both patients who 
were treated with antiviral therapy and those who 
were not. The treated population was divided into pa-
tients who achieved an SVR and those who did not. 
The lack of SVR achievement emerged as a risk factor 
for HCC development. They also showed that an SVR 
reduced the risk of all-cause mortality in patients with 
advanced fibrosis[27]. Innes et al[28] showed similar 
results, confirming that there is a higher risk of HCC 
occurrence after DAA therapy compared to IFN therapy. 
This result reflects a change in the types of patients 
being treated (older with a higher Child-Pugh score, with 
both thrombocytopenic and treatment experienced). A 
major finding from this study was that upon adjusting 
for these differences, the risk of HCC that was associated 
with IFN-free regimens was similar to the risk related 
to INF regimens[28]. Furthermore, Bielen et al[29] did not 
find higher-than-expected early occurrence rates of HCC 
in patients treated with DAA regimens (1.1%; 4/355) 
compared to patients treated with IFN regimens (1.7%; 
1/59). These rates were comparable to the estimated 1% 
per year frequency of HCC that is observed in patients 
with an SVR who were treated with IFN and ribavirin 
dual therapy. Additionally, in a retrospective study by 
Nagata et al[30], the risk rates of HCC occurrence after 
viral eradication were similar between IFN-based and 
IFN-free therapies. After viral eradication, 2.5% of 
patients developed HCC after IFN-based therapy during 
a median follow-up period of 6.8 years, while 1.1% 
of patients developed HCC after DAA therapy during 
a median follow-up period of 1.8 years (p-value: not 
significant). The Nagata study also showed that Wisteria 
floribunda agglutinin and Mac2-binding protein-positive 
(WFA + M2BP) were independently associated with HCC 
occurrence after viral eradication among patients without 
severe fibrosis[30]. Ioannou et al[31] recently published a 
study on 62,354 patients who received antiviral treatment 
in the Veterans Affairs National Healthcare system 
between 1/1/1999 and 12/31/2015. The study included 
35871 (58%) IFN-based regimens, 4535 (7.2%) DAA+ 
IFN regimens and 21948 (35%) DAA-based regimens. 
They identified 3271 incident cases of HCC diagnosed at 
least 180 days after initiation of the antiviral treatment 
over a mean follow-up of 6.1 years. The incidence of 
HCC was highest in patients with cirrhosis and who were 
experiencing treatment failure. SVR was associated 
with a significantly decreased risk of HCC (a 71% risk 
reduction) in the DAA-treated cohort[31]. Kabayashi et 
al[32] demonstrated that the impact of DAA treatment was 
similar to that of IFN treatment with regard to HCC risk 
reduction in patients who achieved a SVR. The 3- and 
5-year cumulative HCC development rates were 1.30% 
and 3.03%, respectively, in the DAA group, and 1.02% 
and 2.19% in the IFN group, respectively. Similarly, 
a study by Nagaoki et al[33] examined the cumulative 
incidence of HCC development after HCV eradication by 
IFN or DAA treatment and found that HCC development 
risk after HCV eradication was similar in patients with 
and without advanced liver fibrosis. A retrospective study 
by Li et al[34] used the Electronically Retrieved Cohort of 
HCV Infected Veterans (ERCHIVES) database (17836 
persons). The study found that DAA treatment was not 
associated with a higher risk of HCC in cirrhotic patients, 
although a significantly higher rate of known risk factors 
for HCC (including cirrhosis, older age and higher base-
line AFP levels) was found in DAA-treated patients 
compared to that in patients treated with IFN. Among 
people with cirrhosis who achieved an SVR, the HCC 
incidence rate was not significantly different in the DAA 
group compared to that in the IFN group. Furthermore, 
both groups had a significantly lower probability of 
HCC compared to patients who received no treatment. 
These results support the concept that treating HCV and 
achieving a SVR with any antiviral regimen is the most 
important determinant for lowering HCC risk[34].
Finally, in a recent meta-analyses (19 prospective, 5 
retrospective, and 2 retrospective-prospective cohorts), 
Waziry et al[35] confirmed that there is no evidence to 
suggest that DAA therapy is associated with a higher 
risk of HCC development after curing HCV with DAA 
therapy in patients with cirrhosis. The treatments reduce 
individual risk by 63%, which is similar to previous 
results from IFN-based treatments. There is thus no 
reason to defer or withhold DAA therapy considering the 
advantages of this therapeutic strategy[35].
In conclusion, the studies comparing the HCC risk 
after DAA to the risk after IFN treatment showed similar 
results, with an SVR being a marker for obtaining a 
clinical advantage. On the other hand, it is important to 
be aware that the two populations are heterogeneous 
and incomparable for age, the presence of comorbidities 
and the stages of cirrhosis. Consequently, it is only 
possible to overcome this bias by statistical adjustment, 
which represents a good approach but is not a definitive 
demonstration. Even in presence of an SVR, patients 
with cirrhosis remain at risk for HCC and should continue 
to undergo HCC surveillance. 
HCV-DAA AND HCC RECURRENCE
Definition of HCC recurrence
HCC recurrence was defined as the reappearance of 
HCC in a subject (with or without an underlying liver 
disease) who previously had HCC that was judged to be 
radically and successfully treated by one of the following 
techniques: surgical resection, liver transplantation, 
ablative techniques or TACE. The 6-mo recurrence rate of 
HCC successfully treated with resection or local ablation 
is estimated to be 20%[36].
Risk of HCC recurrence after treatment with DAAs
Several studies on the recurrence of HCC after DAA 
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treatment produced intriguing data. Table 2 summarises 
the results of the key studies addressing this topic. Figure 
2 shows the HCC cumulative recurrence rates reported 
by 18 studies.
There is ongoing uncertainty about the potential risks 
and benefits of DAA therapy in patients with a history 
of previous HCC. All published data should be analysed 
according to their methodological limitations and should 
consider the large differences between studies in terms 
of follow-up duration, clinical heterogeneity and patient 
selection. Analyses of the recurrence rates should also 
account for the time since previous HCC treatments due 
to the high HCC recurrence rate during the first 2 years 
after HCC treatment. 
The first paper published on this topic came from a 
group in Barcelona[7]. The paper suggested that there is 
a potential increased risk of HCC recurrence after DAA 
treatment. In this multicentre retrospective study, Reig 
et al[7] observed that 16 of 58 (27.6%) patients who 
were treated with DAAs had HCC recurrence after a 
median follow-up of 5.7 mo. They observed that patients 
with a short amount of time between HCC treatment 
and the start of DAA therapy (under 4 mo) seemed to 
be at a greater risk, with a recurrence rate of 41.2%. 
Additionally, 6 patients had HCC recurrence within 2 
wk of initiating their DAA treatment[7]. Moreover, after 
updating their cohort (with more patients who were 
followed for a longer time period), the updated results 
not only confirmed their initial findings but also exposed 
a more aggressive pattern of recurrence and a faster 
tumour progression[37,38].
At the same time, Conti et al[8] found that 17 out of 
59 patients (29%) had HCC recurrence during the first 
24 wk of follow-up after completing their DAA treatment. 
Recurrence was associated with being of a younger age 
and having more severe liver fibrosis[8]. Similarly, Calleja 
et al[14] reported an HCC recurrence rate of 30% within 
12 mo of starting DAA treatment. 
Three later retrospective studies reported a high 
rate of HCC recurrence after treatment with DAAs in 
cirrhotic patients[39,40] and in patients who underwent 
liver transplants[41]. The European multicentre study by 
Kolly et al[39] reported an HCC disease-free survival rate 
of 77% at six months after HCV therapy. This finding 
is in line with the findings reported by Reig et al[7] and 
Conti et al[8]. In this study, the time between the HCC 
treatment and the start of the DAA therapy was a 
significant, time-dependent predictor of recurrence. An 
Egyptian prospective study by El Kassas et al[40] showed 
that exposure to DAA treatment was associated with a 
significantly increased risk of HCC recurrence of 3.82 
over a median follow-up period of 16 mo, compared 
to non-exposed patients. Yang et al[41] reported an 
increased risk of recurrence of HCC in a small group of 
transplant patients who received DAA therapy while they 
were waiting for their liver transplant. HCC recurrence 
was more frequently observed in DAA-treated recipients 
than untreated patients (27.8% vs 9.5%). Moreover, 
HCC recurrence occurred very early after the transplant 
(< 6 mo) in most recipients, with a higher frequency in 
the DAA-treated group compared to the untreated group 
(80% vs 33%). In most of cases, HCC recurred as an 
extrahepatic disease[41].
Despite the lower rate of occurrence after DAA treat-
ment found in a cohort examined by Bielen et al[29], 
there was a high early recurrence rate of HCC (15%) 
within 6 mo after DAA treatment. In contrast, with a 
report by Yang et al[41], patients with HCC recurrence 
had a lower SVR rate. Interestingly, only patients 
who were treated with LR or RFA for the primary HCC 
experienced recurrences, whereas patients treated 
with liver transplantation (LT) did not. However, very 
recently Huang et al[42] performed a retrospective 
cohort study of 149 LT candidates with HCV and HCC to 
determine the impact of DAAs on HCC recurrence after 
local-regional therapy (LRT) and waitlist dropout. They 
showed advanced cirrhosis and lower rates of complete 
radiologic tumour response after LRT in patients who 
were not treated with DAAs (n = 87) compared to 
patients treated with DAA (n = 62). The cumulative 
incidence of HCC recurrence within 1-year of complete 
response after LRT was 47.0% in the DAA group and 
49.8% in the untreated group (p = 0.93). In an adjusted 
competing risk analysis that used weighted propensity 
score modelling, the risk of HCC recurrence was similar 
between the DAA and the untreated groups (HR = 0.91, 
95%CI: 0.58-1.42, p = 0.67). Patients treated with 
DAA had a lower risk of waitlist dropout due to tumour 
progression or death compared to the untreated group 
in the adjusted, weighted analysis (HR = 0.30, 95%CI: 
0.13-0.69, p = 0.005)[42].
In contrast, the large ANRS study from France used 
three different prospective cohorts of HCC patients 
previously treated with curative therapies (including LT). 
The study reported no differences in the recurrence rates 
of patients who were treated with DAAs and those who 
were not[43]. Similarly, Zeng et al[18] and Torres et al[44] 
published their own prospective studies with median 
follow-up times of 12 and 15 mo, respectively. Both 
studies reported that there were no HCC recurrences 
among any of their patients. 
Ikeda et al[45] then showed that DAA therapy signi-
ficantly decreased recurrence rate when it is performed 
after an initial successfully HCC therapy, compared with 
the recurrence rate in untreated patients. They analysed 
a total of 270.81 patient-years, with 61 recurrence 
events (median follow-up of 20.7 mo). The 1- and 2-year 
cumulative recurrence rates in the DAA cohort were 
30.1% and 38.9%, respectively. The HCC recurrence 
rate was significantly higher in patients with a history of 
previous recurrence or multiple treatments for HCC[45]. 
Additionally, Virlogeux et al[46] confirmed this trend by 
showing that the HCC recurrence rate was significantly 
lower among patients treated with DAAs compared with 
untreated patients (1.7/100 person-months vs 4.2/100 
person-months, respectively). Similarly, Zavaglia et al[47] 
reported a recurrence rate of 3.1% over a median follow-
up of 8 mo. They suggested that the longer time interval 
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Ref. Journal, year Country Study design Sample 
size
Previous HCC 
treatment
Median 
follow-up 
(mo)
HCC 
recurrence 
rate (%)
Risk factors Notes
Reig 
et al[7,37,38]
J Hepatol, 2016 
and 2017 -
Semin Liv Dis, 
2017
Spain Retrospective 77 Ablation, 
resection, TACE
11.2 27.3 NA Updated 
cohort of the 
58 patients 
reported in J 
Hepatol 2016
Conti 
et al[8]
J Hepatol, 2016 Italy Retrospective 59 Ablation, 
resection, TACE
12 28.8 age, liver stiffness     - 
ANRS 
- HEPATHER 
et al[43]
J Hepatol, 2016 France Prospective 189 NA 20 12.7 NA     - 
ANRS 
- CirVir 
et al[43]
J Hepatol, 2016 France Prospective 13 Ablation, 
resection
16.5 7.7 NA     - 
ANRS 
- CUPILT 
et al[43]
J Hepatol, 2016 France Prospective 314 Bridge therapy 
before LT 
(Ablation, 
resection, TACE, 
chemotherapy)
7 2.2 NA     - 
Calleja 
et al[14]
J Hepatol, 2017 Spain Retrospective 70 NA 20 30 NA     - 
Cabibbo 
et al[50]
APT, 2017 Italy Prospective 143 Ablation, 
resection, TACE
9 21 previous recurrence, 
tumour size
    - 
Minami 
et al[55,56]
J Hepatol 2016 
- Abs AASLD 
2017
Japan Retrospective 163 Ablation, 
resection, TACE, 
radiotherapy
14.5 54.4 AFP-L3, DCP, number 
of previous treatment 
for HCC, interval 
between last HCC 
treatment and DAA 
start
Abstract of 
AASLD 2017
Virlogeux 
et al[46]
Liver Int 2017 France Retrospective 23 Ablation, 
resection, TACE
13 47.8 NA     - 
Zeng 
et al[18]
J Hepatol, 2016 China Retrospective 10 Ablation 15 0 NA Letter to Editor
Ogawa 
et al[48]
Aliment 
Pharmacol Ther, 
2017
Japan Prospective 152 Ablation, 
resection, TACE, 
radiotherapy
17 16.5 cirrhosis, time from 
previous HCC 
treatment < 1 yr, 
non-curative HCC 
treatment (TACE, 
radiotherapy)
- 
Cheung 
et al[15]
J Hepatol 2016 United 
Kingdom
Prospective 29 NA 15 6.8 NA     - 
Torres 
et al[44]
J Hepatol 2016 United 
States
Prospective 8 Ablation, 
resection, proton 
therapy
12 0 NA Letter to Editor
Yang 
et al[41]
J Hepatol 2016 United 
States
Prospective 18 Bridge therapy 
before LT: 
Ablation, TACE
NA 27.8 NA Letter to Editor; 
untreated 
patients: 9.5%
Bielen 
et al[29]
J Viral Hepat 
2017
Belgium Retrospective 41 LT, ablation, 
resection, TACE
32 14.6 SVR     - 
Ikeda 
et al[45]
Dig Dis Sci 
2017
Japan Retrospective 177 Ablation, 
resection, TACE, 
radiotherapy
20.7 34.5 multiple HCC 
treatment, AFP level, 
Prothrombin time
- 
Kolly 
et al[39]
J Hepatol 2017 Germany, 
Belgium, 
Switzerland
Prospective 56 Ablation, 
resection, TACE
21 42.5 time from previous 
HCC treatment
Letter to Editor
Nagata 
et al[30]
J Hepatol 2017 Japan Retrospective 83 Ablation, 
resection
27.6 29 SVR, AFP, WFA-M2BP     - 
Shimizu 
et al[52]
Indian J 
Gastroenterol 
2017
Indian Retrospective 23 RFA, TACE, 
radiation
NA 43 HBcAb positivity, 
TACE
-
Mashiba 
et al[57]
Plos one 2018 Japan Retrospective 368 NA 24 NA AFP level,  SVR, 
clinical stage of HCC
-
Table 2  Main characteristics of the studies on hepatocellular carcinoma recurrence
AFP: Alpha-fetoprotein; DAAs: Direct-acting antiviral agents; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; LR: Liver resection; LRT: 
Local-regional therapy; LT: Liver transplantation; SVR: Sustained virological response; RFA: Radiofrequency ablation; TACE: Trans-catheter arterial 
chemoembolization; NA: Not available.
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between complete eradication of the tumour and the start 
of the antiviral therapy (median 19.3 mo in this study 
and 11.2 mo in a study by Reig) may explain part of the 
observed difference. In fact, the longer this interval, the 
lower the risk that any residual tumour would be present 
at the start of DAA therapy[47]. A large multicentre cohort 
study conducted by Ogawa et al[48] showed no evidence 
of an increased risk of HCC recurrence in patients treated 
with DAA regimens. The study included 152 consecutive 
patients with a history of previous HCC who achieved 
an SVR after treatment with DAAs. During the follow-up 
period (median: 17 mo), 16.5% of patients developed 
HCC. The 1-year cumulative HCC recurrence rate was 
23.1% when limited to cirrhotic patients[48]. Mazzarelli 
et al[49] commented that the risk of HCC recurrence may 
have been higher because there was a relatively short 
amount of time between the successful completion of 
the HCC treatment and the initiation of the DAAs. This 
suggests that patients may not have sufficient time to be 
deemed cancer-free.
Moreover, a large prospective study by Cabibbo 
et al[50] found that the 6-mo and 1-year probabilities 
of HCC recurrence after DAA therapy were 12% and 
26.6%, respectively. Previous history of HCC recurrence 
and tumour size were the only two independent risk 
factors for early HCC recurrence. They concluded that 
the probability of early recurrence in patients who had 
previously been cured of HCC remained high, despite 
HCV eradication by DAA treatment. This risk was com-
parable, but not higher than, the risk reported in the 
literature concerning patients who did not receive DAA 
treatment[50].
Beste et al[51] reported that HCV can be cured in the 
majority of patients with HCC, in virtually all patients 
with a prior history of HCC and in patients who receive 
subsequent LT. The study also reported that these 
patients do not have an increased risk of recurrence. 
Compared to others, this study benefited from its use of 
a large cohort of HCC patients (624 HCC patients from 
17487 HCV treatment recipients). HCC patients were 
divided into those who were treated with LT after HCC 
diagnosis (‘‘HCC/LT” group) and those who were treated 
with other modalities (‘‘HCC” group) prior to receiving 
DAA therapy. Overall, the SVR was 91.1% in the non-
HCC patients, 74.4% in the HCC patients and 94.0% 
in the HCC/LT patients[51]. In addition, Shimizu et al[52] 
identified the anti-HBc positivity as a strong contributing 
factor for HCC recurrence after DAA therapy. In fact 8/10 
patients with a positive value of anti-HBc developed HCC 
recurrence (80%), in the context of an overall recurrence 
rate of 43% in their 23 enrolled patients. So checking for 
anti-HBc seems to be mandatory before starting DAA 
therapy[52].
From a radiological point of view, a study of Renzulli 
et al[53] showed that in HCC, microvascular invasion 
(MVI) is a predictor of early HCC recurrence. In fact, in 
their retrospective study of patients who received DAA 
therapy, HCC was diagnosed in 29 of the 344 cirrhotic 
patients after DAA treatment (3.86% de novo HCC and 
30.5% recurrent HCC). Both de novo and recurrent 
neoplastic nodules showed a significantly higher pro-
portion of MVI (70.7%) than nodules that occurred 
before DAA therapy (33.3%). This finding supports the 
hypothesis that there is a similar oncogenic process after 
DAA therapy regardless of the patient’s history of HCC[53].
As a basis for comparison, recently Cabibbo et al[54] 
published a meta-analysis of 11 studies evaluating the 
HCC recurrences in HCV untreated patients. Patients in 
the studies included in the meta-analysis were charac-
terized by an early HCC and a complete response after 
surgical resection or ablation. The meta-analysis reported 
that the actuarial probabilities of recurrence were 7.4%, 
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20% and 47% at six months, one year and two years, 
respectively. These data revealed a pooled 3-year survival 
probability of 79.8%. The authors highlighted that there 
was a high level of heterogeneity among studies on 
the recurrence and survival rates. They also reported 
that, currently, there is no clinical feature-based scoring 
system that accounts for the molecular characteristics 
and pathobiology of the tumours (invasiveness, doubling 
time, angiogenesis and microvascular invasion). These 
pooled, reported recurrence and survival probabilities 
provide a useful benchmark for making indirect com-
parisons of the benefits of HCV eradication using 
DAAs[54].
Several risk factors have been identified that may 
increase the risk of HCC recurrence after DAA treatment 
(Table 2), such as high liver stiffness, antiviral treatment 
failure, history of previous HCC recurrence, previous 
HCC shape and stage, AFP level values, des-γ-carbossi-
prothrombin (DCP) > 40 mAU/mL, non-curative pro-
cedures (such as TACE), anti-HBc positivity, the time 
interval between HCC complete response and DAA 
initiation and the levels of WFA + M2BP[8,30,48,50,52,55-57].
In conclusion, DAA treatment does not reduce HCC 
recurrence risk, though we do not have sufficient data to 
assume that the recurrence rate is actually increased due 
to the lack of adequate control groups in many studies.
Comparing  the risk of HCC recurrence after DAAs vs 
after IFN-based treatments
While there are few comparative studies examining 
patients receiving IFN treatment[28,33,54,55], the data 
suggest that DAA-treated patients have a similar risk of 
HCC recurrence as patients receiving IFN-treatments and 
untreated patients. However, these analyses are limited 
by several potential confounders such as the degree of 
liver function or the age of the patients. 
A recent meta-analysis published by Waziry et al[35] 
reported that there was no evidence for different HCC 
recurrence risks following an SVR from DAA and IFN-
based therapies. In this study, the baseline characteristics 
of the IFN- and DAA-cured populations were similar, 
including age and stage of cirrhosis, given that HCC is 
more likely to develop in older cirrhotic patients and that 
patients with advanced cirrhosis (Child- Pugh B/C) are 
not eligible for potentially curative HCC treatments.
Similarly, comparing 57 patients who were treated 
with IFN-based therapies to the 58 patients from the Reig 
et al[7] study whose HCC was successfully treated with 
DAAs, Petta et al[58] found recurrence rates of 3.7% vs 
5.2% at six months, and 15.2% vs 26.3% at two years, 
respectively, with no statistically significant differences.
Vukotic el al[59] confirmed this trend and demon-
strated the benefit of an SVR. In a retrospective study, 
they sought to compare the HCC recurrence-free sur-
vival of a historical cohort treated with IFN (SVR rate 
of 31.6%), an untreated cohort and a cohort treated 
with DAAs (SVR of 93.8%) with a median follow-up 
duration of 42 mo. In the two treated groups, the time 
to HCC recurrence measured from the start of the anti-
viral therapy was lower in the group that was treated 
with DAAs compared to the group treated with IFN, 
confirming the beneficial role of a SVR. However, in such 
retrospective comparisons, the majority of the DAA-
treated cohorts had much shorter follow-up periods after 
antiviral therapy than the historical IFN-based cohorts. 
Interestingly, the median time to HCC recurrence since 
the last HCC treatment was significantly higher in both of 
the treated groups compared to the untreated cohort[59].
In a case-control study, Adhoute et al[60] suggested 
that DAA treatment should be started after a longer 
period of follow-up following the successful treatment 
of HCC. They suggested that a follow-up duration of 
least 12 mo be used to reduce the risk of early HCC 
recurrence[60]. Nagata et al[30] showed that there were 
no statistically significant differences between the DAA- 
and IFN-based therapies in terms of HCC recurrence. 
Specifically, 18 (53%) patients with a history of HCC had 
a recurrence after receiving IFN-based therapy over a 
median follow-up period of 6.2 years. For those treated 
with DAAs, 22 patients (29%) had an HCC recurrence 
over a median follow-up period of 2.3 years[30].
Finally Mashiba et al[57] analysed a Japanese cohort 
(556 patients) with 148 patients underwent IFN and 
achieving SVR in 52.7 % of cases, and 368 patients 
treated with DAA treatment achieving SVR in the 
94.5%. The mean follow-up period after antiviral ther-
apy was 25.5 mo for the IFN group and 7.7 mo for 
the DAA group. The DAA group was significantly older 
and included more patients with advanced fibrosis, a 
population at higher risk of HCC recurrence. Nonetheless, 
there were no differences in the recurrence rate between 
IFN and DAA therapy in SVR patients. Moreover, they 
identified AFP at the end of antiviral therapy, clinical stage 
of HCC, and antiviral treatment failure as independent 
factors associated with early recurrence of HCC[57]. 
The scientific debate on this topic has been particu-
larly intense, which is likely a consequence of the limited 
number of studies and the high heterogeneity related to 
the study design, inclusion criteria, baseline patient and 
tumour characteristics, type of “curative” HCC treatment 
and assessment of response, time frame between tu-
mour treatment and DAAs therapy and between the last 
assessment of tumour response and the DAA therapy 
and follow-up after DAA therapy. Nonetheless, we can 
conclude that the available evidence supports that DAA-
treated patients have a similar risk for HCC recurrence as 
IFN-treated patients.
BIOMOLECULAR MECHANISMS OF HCC 
OCCURRENCE AND RECURRENCE AFTER 
DAA
Different pathogenetic hypotheses have been postulated 
to support the development of HCC after DAA therapy. 
These hypotheses are mainly based on the dysregulation 
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of immune surveillance caused by the rapid decrease of 
HCV viral load induced by the DAAs[7], as also recently 
suggested by Kanda et al[61]. The rapid disappearance 
of HCV with DAA therapy leads to the reconstitution of 
innate immunity and the downregulation of type Ⅱ and 
Ⅲ IFNs, their receptors and IFN-stimulated genes. The 
lack of IFN activation may allow the growth of malignant 
cells. IFNs are known to exert anti-proliferative effects via 
intrinsic effects on the tumour regulation of angiogenesis 
and the activity of almost all immune cell types. This 
induces a strong immune response against malignancy. 
Although the exact mechanism behind the anti-tumour 
properties of IFN has not been fully elucidated, IFN 
has been widely used for the treatment of several 
cancers, including haematological malignancies and 
solid tumours[62]. Unlike IFN, DAAs have neither anti-
angiogenic nor anti-proliferative properties and indeed 
have no effect on oncogenic buds.
Another speculated mechanism is the altered im-
munological balance that is secondary to a rapid de-
crease in HCV viral load that contributes to tumour 
development[63]. A rapid decrease in cancer immuno-
surveillance due to an abrupt reduction of liver natural 
killer (NK) cells and of their cytotoxic activity has been 
suggested to be a possible factor enhancing a faster 
progression of HCC foci[64]. Debes et al[65] identified a 
group of 12 immune mediators showing significantly 
higher serum expression levels before DAA treatment in 
patients who developed subsequent HCC. The authors 
measured serum immune mediators in a cohort of 13 
patients who developed HCC (10 occurrences and 3 
recurrences) after DAA therapy and compared them to 
10 matched controls who did not develop HCC during 
the follow-up period. In this analysis, the level of TNF 
α decreased 4 wk after DAA treatment in the controls, 
while it remained stable in patients who developed HCC. 
This observation suggests that the persistence of high 
levels of TNF-α may be involved in the development of 
HCC[65].
Ono et al[66] suggested that the persisting risk of 
hepatocellular carcinoma after curing HCV could be moni-
tored by a liver transcriptome signatures. They underlined 
the necessity to identify a predictive molecular biomarker 
to stratify the risk of HCC after surgical resection. Finally, 
a recent study by Villani et al[67] supported this idea by 
demonstrating that during treatment with DAAs, an an-
giogenesis inducer (vascular endothelial growth factor) 
increased significantly and remained elevated for 3 mo 
after DAA treatment. Most of these theories remain to 
be confirmed and further studies are urgently needed to 
better understand the biological mechanisms underlying 
the hepatocarcinogenesis following viral eradication.
Faillaci et al[68] analysed RNA extracted from hepatic 
tissue of 242 patients (of whom 183 with cirrhosis) 
treated with DAAs and showed that Angiopoietin-2 levels 
were significantly higher in patients with recurrent (n 
= 14) and de novo HCC (n = 21) in comparison with 
those without HCC. Moreover, they demonstrated that 
DAAs are not per se able to determine the occurrence or 
recurrence of HCC, but that the DAA-mediated increase 
in VEGF acts as a trigger in predisposed patients, namely 
those with severe fibrosis and splanchnic collateralization, 
who already have abnormal activation in liver tissues 
of neo-angiogenetic pathways, as shown by increased 
Angiopoietin-2. Therefore, we can postulate that the 
combination of the clinical and biologic risk factors could 
give us the unique possibility of selecting the patients at 
real risk of developing HCC after DAAs[68].
For all these reasons, the use of serum biomarkers for 
HCC detection and follow-up, as currently recommended 
only by Asiatic guidelines, is becoming a necessity. 
Several microRNAs or others epigenetic molecules have 
been proposed for HCC detection, but the absence of a 
standardized method for their quantification is a major 
technical concern regarding the use of microRNAs as 
reliable markers[69].
In conclusion, patients with HCV cirrhosis who succes-
sfully underwent resection or ablation for HCC must 
undergo DAA therapy to prevent liver disease progres-
sion and decompensation. No accurate scientific evidence 
supports an increased risk of HCC recurrence.
CONCLUSION
In summary, in this review, we analysed the published 
data on the risk of developing HCC after DAA therapy, 
measured as the risks of occurrence and recurrence. 
The available data are conflicting, and the studies show 
different and relevant methodological limitations. There-
fore, drawing definitive conclusions from these studies 
is difficult. On the other hand, the use of DAAs does not 
appear to increase the occurrence or recurrence of HCC. 
Ongoing multicentre prospective studies should provide 
some insight into this controversial issue. It has been 
pointed out that there is not an adequate control group 
for patients treated with DAAs because the population is 
very different from the historical population of untreated 
or IFN-treated patients. Therefore, a longer follow-up 
period and the selection of patients for making a control 
group is required to establish whether there is a real 
risk of HCC with IFN-free therapy or, inversely, if there 
is a real advantage of this new antiviral drug in terms of 
HCC occurrence and recurrence. Therefore, it is prudent 
to wait at least 12 mo after complete HCC response to 
initiate DAA therapy.
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